Leap Therapeutics (id:6957 LPTX)
2.55 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 12:48:01 AM)
Exchange closed, opens in 1 day 8 hours
About Leap Therapeutics
Market Capitalization 124.36M
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
| Headquarters (address) |
47 Thorndike Street Cambridge 02141 MA United States |
| Phone | 617 714 0360 |
| Website | https://www.leaptx.com |
| Employees | 54 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | LPTX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.68 - 5.00 |
| Market Capitalization | 124.36M |
| P/E trailing | -0.673 |
| P/E forward | -2.60 |
| Price/Book | 1.89 |
| Beta | 0.217 |
| EPS | -0.980 |
| EPS United States (ID:6, base:3403) | 24.22 |